First report of COVID-19 vaccine induced flare of compensated congenital thrombotic thrombocytopenic purpura

Dykes, Kaitlyn; Kessler, Craig M.

doi:10.1097/mbc.0000000000001097

Cited by 10 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients receiving FFP infusion were vaccinated within 2 weeks of FFP infusion. In contrast, the patient reported by Dykes et al underwent vaccination 6 weeks after OctaPlas™ (solvent/detergent treated, pooled human plasma) infusion and developed ischemic stroke 1 week after vaccination [6]. We hypothesize that a long interval between plasma infusion and vaccination could be a risk factor for cTTP exacerbation.…”

mentioning

confidence: 65%

“…Recently, Dykes et al reported a case in which COVID-19 vaccination exacerbated the cTTP condition [6]. This patient developed an acute ischemic stroke with mild thrombocytopenia shortly after receiving the COVID-19 vaccine (mRNA-1273).…”

mentioning

confidence: 99%

“…Theoretically, patients with cTTP are at a high risk for thrombosis due to COVID-19 infection. This is attributed to the increase in plasma von Willebrand factor levels and decrease in plasma ADAMTS13 activity with disease severity in patients with COVID-19 infection [5].Recently, Dykes et al reported a case in which COVID-19 vaccination exacerbated the cTTP condition [6]. This patient developed an acute ischemic stroke with mild thrombocytopenia shortly after receiving the COVID-19 vaccine (mRNA-1273).…”

mentioning

confidence: 99%

See 2 more Smart Citations

No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey

et al. 2022

View full text Add to dashboard Cite

Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare disorder caused by severe ADAMTS13 deficiency [1]. Between 2001 and 2020, only 226 patients with cTTP were reported worldwide [2]. As of 2021, we identified 67 patients with cTTP in Japan alone [3,4]. Theoretically, patients with cTTP are at a high risk for thrombosis due to COVID-19 infection. This is attributed to the increase in plasma von Willebrand factor levels and decrease in plasma ADAMTS13 activity with disease severity in patients with COVID-19 infection [5].Recently, Dykes et al. reported a case in which COVID-19 vaccination exacerbated the cTTP condition [6]. This patient developed an acute ischemic stroke with mild thrombocytopenia shortly after receiving the COVID-19 vaccine (mRNA-1273). To date, over 10 cases of de novo immune TTP have been reported following COVID-19 vaccination worldwide [7,8]. However, there have been no other reports of COVID-19 vaccine-induced flare of cTTP. In Japan, two types of mRNA-based vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), are available. We administered a questionnaire survey in Japanese patients with cTTP regarding the adverse events after vaccination in October 2021, when double doses of vaccinations were almost completed in Japanese applicants who were ≥ 12 years of age.The questionnaire was sent to physicians who were treating patients with cTTP. Of the 67 Japanese patients with cTTP, 58 were alive and 6 were under 12 years of age. According to the questionnaire survey of 42 patients, 38 had completed vaccination twice, and 4 patients had not * Masanori Matsumoto

show abstract

mentioning

confidence: 65%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Cases were observed in patients with an age range of 14–84 years, with 11 out of 17 patients being female. While the majority of cases were considered aTTP, there was one case of a relapse in congenital TTP (cTTP) [ 2 ] reported with the Moderna vaccine. Twelve out of 17 patients had their first TTP episode, while in 5 patients it was a relapse of known disease.…”

Section: The Casementioning

confidence: 99%

“…In a separate case study, a 50-year-old female patient [ 2 ] with cTTP developed vaccine-associated TTP 7 days after the second vaccination with the Moderna vaccine. This patient had an ADAMTS13 activity of < 5% with no proof of ADAMTS13 antibodies.…”

Section: The Casementioning

confidence: 99%

Thrombotic thrombocytopenic purpura after vaccination for COVID-19: lesson for the clinical nephrologist

et al. 2022

View full text Add to dashboard Cite

New‐onset and relapsed thrombotic microangiopathy post‐COVID‐19 vaccination

2023

Journal of Medical Virology

View full text Add to dashboard Cite

Thrombotic microangiopathy (TMA) associated with coronavirus disease 2019 (COVID-19) vaccination has been reported, however, the clinical characteristics and pathogenesis remained mysterious. We reviewed 84 TMA cases post-COVID-19 vaccination, including 64 patients diagnosed with thrombotic thrombocytopenic purpura (TTP), 17 cases presented as atypical hemolytic uremic syndrome (aHUS), and three cases manifested as unclassified TMA. TMA episodes were mostly associated with messenger RNA vaccines. For TTP, 67.6% of females developed symptoms after the first dose of the vaccine, and 63.0% of males were secondary to the second dose (p = 0.015). Compared with TTP, aHUS generally appeared within 7 days (p = 0.002) and showed higher levels of serum creatinine (p < 0.001). 87.5% of TTP received plasma exchange (PEX)-based treatment, and 52.9% of aHUS adopted non-PEX-based therapies (p < 0.001). Mechanistically, complement dysfunction, neutrophil activation, and the generation of pathogenic autoantibodies resulting from molecular mimicry contribute to explaining the pathogenesis of TMA post-COVID-19 vaccination.

show abstract

First report of COVID-19 vaccine induced flare of compensated congenital thrombotic thrombocytopenic purpura

Cited by 10 publications

References 7 publications

No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey

No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey

Thrombotic thrombocytopenic purpura after vaccination for COVID-19: lesson for the clinical nephrologist

New‐onset and relapsed thrombotic microangiopathy post‐COVID‐19 vaccination

Contact Info

Product

Resources

About